News

Eylea is approved for sale in the US and Australia for the treatment of neovascular age-related macular degeneration (wet AMD). Under the agreement, Bayer owns the exclusive marketing

The company also posted a net loss of $73,000, or $0.00 per share, compared to net earnings of $143,000, or $0.01 per share, for the same quarter in

The 74mcg once-daily product is indicated for the treatment of both ocular and nasal symptoms associated with seasonal allergic rhinitis and the treatment of nasal symptoms associated with

VIvus will market the product under the brand name Stendra in the US. Mitsubishi Tanabe Pharma has discovered TA-1790 as ED therapy, which is expected to have an

With the termination of the agreement, Aeterna has regained the North American rights to perifosine, in all indications. Aeterna announced the continuation of the ongoing Phase 3 trial

The collaboration will focus on the development, manufacturing and commercialization of biosimilar forms of etanercept and rituximab developed by Coherus. Daiichi president and CEO Joji Nakayama said, "By

The funds will support a center, to be named the Pii Center for Pharmaceutical Technology, focused on research related to hot melt extrusion and other pharmaceutical processing technologies.

The transaction was finalized on the 30 April 2012 and the other terms related to the transaction are confidential. Chesapeake CEO Mike Cheetham said, "This acquisition will enable

The new ZAR300m ($38.3m) facility is in compliance with the international Pharmaceutical Inspection Convention and Pharmaceutical Co-operation Scheme Standards adopted by the South African Medicines Control Council. Adcock